Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease

Autores
Crispo, James; Farhat, Nawal; Fortin, Yannick; Perez Lloret, Santiago; Sikora, Lindsey; Morgan, Rebecca L.; Habash, Mara; Gogna, Priyanka; Kelly, Shannon E.; Elliott, Jesse; Kohen, Dafna E.; Bjerre, Lise M.; Mattison, Donald R.; Hessian, Renée C.; Willis, Allison W.; Krewski, Daniel
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos. NOSM University; Canadá
Fil: Farhat, Nawal. University of Ottawa; Canadá
Fil: Fortin, Yannick. University of Ottawa; Canadá
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Sikora, Lindsey. University of Ottawa; Canadá
Fil: Morgan, Rebecca L.. Mc Master University; Canadá
Fil: Habash, Mara. Cancer Care; Canadá
Fil: Gogna, Priyanka. Queens University; Canadá
Fil: Kelly, Shannon E.. University of Ottawa; Canadá
Fil: Elliott, Jesse. University of Ottawa; Canadá
Fil: Kohen, Dafna E.. University of Ottawa; Canadá
Fil: Bjerre, Lise M.. University of Ottawa; Canadá. Institut du Savoir Montfort; Canadá
Fil: Mattison, Donald R.. University of Ottawa; Canadá. Risk Sciences International; Canadá
Fil: Hessian, Renée C.. University of Ottawa; Canadá
Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos
Fil: Krewski, Daniel. University of Ottawa; Canadá. Risk Sciences International; Canadá
Materia
Parkinson's disease
Dopamine agonists
Cardiovascular adverse reactions
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/274454
Acceder
id CONICETDig_4a564ab66fdc3d4e9fba842b5a1462f1
oai_identifier_str oai:ri.conicet.gov.ar:11336/274454
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s DiseaseCrispo, JamesFarhat, NawalFortin, YannickPerez Lloret, SantiagoSikora, LindseyMorgan, Rebecca L.Habash, MaraGogna, PriyankaKelly, Shannon E.Elliott, JesseKohen, Dafna E.Bjerre, Lise M.Mattison, Donald R.Hessian, Renée C.Willis, Allison W.Krewski, DanielParkinson's diseaseDopamine agonistsCardiovascular adverse reactionshttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos. NOSM University; CanadáFil: Farhat, Nawal. University of Ottawa; CanadáFil: Fortin, Yannick. University of Ottawa; CanadáFil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Sikora, Lindsey. University of Ottawa; CanadáFil: Morgan, Rebecca L.. Mc Master University; CanadáFil: Habash, Mara. Cancer Care; CanadáFil: Gogna, Priyanka. Queens University; CanadáFil: Kelly, Shannon E.. University of Ottawa; CanadáFil: Elliott, Jesse. University of Ottawa; CanadáFil: Kohen, Dafna E.. University of Ottawa; CanadáFil: Bjerre, Lise M.. University of Ottawa; Canadá. Institut du Savoir Montfort; CanadáFil: Mattison, Donald R.. University of Ottawa; Canadá. Risk Sciences International; CanadáFil: Hessian, Renée C.. University of Ottawa; CanadáFil: Willis, Allison W.. University of Pennsylvania; Estados UnidosFil: Krewski, Daniel. University of Ottawa; Canadá. Risk Sciences International; CanadáMultidisciplinary Digital Publishing Institute2024-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/274454Crispo, James; Farhat, Nawal; Fortin, Yannick; Perez Lloret, Santiago; Sikora, Lindsey; et al.; Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease; Multidisciplinary Digital Publishing Institute; Brain Sciences; 14; 8; 7-2024; 1-332076-3425CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2076-3425/14/8/776info:eu-repo/semantics/altIdentifier/doi/10.3390/brainsci14080776info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-11-12T09:33:13Zoai:ri.conicet.gov.ar:11336/274454instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-11-12 09:33:13.816CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
title Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
spellingShingle Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
Crispo, James
Parkinson's disease
Dopamine agonists
Cardiovascular adverse reactions
title_short Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
title_full Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
title_fullStr Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
title_full_unstemmed Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
title_sort Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease
dc.creator.none.fl_str_mv Crispo, James
Farhat, Nawal
Fortin, Yannick
Perez Lloret, Santiago
Sikora, Lindsey
Morgan, Rebecca L.
Habash, Mara
Gogna, Priyanka
Kelly, Shannon E.
Elliott, Jesse
Kohen, Dafna E.
Bjerre, Lise M.
Mattison, Donald R.
Hessian, Renée C.
Willis, Allison W.
Krewski, Daniel
author Crispo, James
author_facet Crispo, James
Farhat, Nawal
Fortin, Yannick
Perez Lloret, Santiago
Sikora, Lindsey
Morgan, Rebecca L.
Habash, Mara
Gogna, Priyanka
Kelly, Shannon E.
Elliott, Jesse
Kohen, Dafna E.
Bjerre, Lise M.
Mattison, Donald R.
Hessian, Renée C.
Willis, Allison W.
Krewski, Daniel
author_role author
author2 Farhat, Nawal
Fortin, Yannick
Perez Lloret, Santiago
Sikora, Lindsey
Morgan, Rebecca L.
Habash, Mara
Gogna, Priyanka
Kelly, Shannon E.
Elliott, Jesse
Kohen, Dafna E.
Bjerre, Lise M.
Mattison, Donald R.
Hessian, Renée C.
Willis, Allison W.
Krewski, Daniel
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Parkinson's disease
Dopamine agonists
Cardiovascular adverse reactions
topic Parkinson's disease
Dopamine agonists
Cardiovascular adverse reactions
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos. NOSM University; Canadá
Fil: Farhat, Nawal. University of Ottawa; Canadá
Fil: Fortin, Yannick. University of Ottawa; Canadá
Fil: Perez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Sikora, Lindsey. University of Ottawa; Canadá
Fil: Morgan, Rebecca L.. Mc Master University; Canadá
Fil: Habash, Mara. Cancer Care; Canadá
Fil: Gogna, Priyanka. Queens University; Canadá
Fil: Kelly, Shannon E.. University of Ottawa; Canadá
Fil: Elliott, Jesse. University of Ottawa; Canadá
Fil: Kohen, Dafna E.. University of Ottawa; Canadá
Fil: Bjerre, Lise M.. University of Ottawa; Canadá. Institut du Savoir Montfort; Canadá
Fil: Mattison, Donald R.. University of Ottawa; Canadá. Risk Sciences International; Canadá
Fil: Hessian, Renée C.. University of Ottawa; Canadá
Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos
Fil: Krewski, Daniel. University of Ottawa; Canadá. Risk Sciences International; Canadá
description Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
publishDate 2024
dc.date.none.fl_str_mv 2024-07
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/274454
Crispo, James; Farhat, Nawal; Fortin, Yannick; Perez Lloret, Santiago; Sikora, Lindsey; et al.; Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease; Multidisciplinary Digital Publishing Institute; Brain Sciences; 14; 8; 7-2024; 1-33
2076-3425
CONICET Digital
CONICET
url http://hdl.handle.net/11336/274454
identifier_str_mv Crispo, James; Farhat, Nawal; Fortin, Yannick; Perez Lloret, Santiago; Sikora, Lindsey; et al.; Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson’s Disease; Multidisciplinary Digital Publishing Institute; Brain Sciences; 14; 8; 7-2024; 1-33
2076-3425
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2076-3425/14/8/776
info:eu-repo/semantics/altIdentifier/doi/10.3390/brainsci14080776
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1848597039558950912
score 12.976206

Publicaciones similares